September 23, 2021 5:26pm
Pre-open indication results: 4 Hits and 2 MISS
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing!
Who else is tracking a broad representative index of cell and gene therapy equities – the facts are supported by real numbers?
The Dow closed UP +56.50 points (+1.48%); the S&P closed UP +53.34 points (+1.71%) while the Nasdaq closed UP +155.40 points (+1.04%)
Henry’omics:
Indexes jumped for a second day as the Fed kept current monetary stimulus in place for just a little bit longer.
Thursday gains moved the Dow +0.05% and S&P +0.03% as the Nasdaq crept 0.06% higher for the week.
RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines:
- Thursday opened positive at 24/6, 4 flats and 1 acquired, stayed positive at the mid-day at 20/13, 2 flats, 1 flat and 1 acquired, closing positive at 29/5 and 1 acquired;
RegMed Investors’ (RMi) pre-open: “I have a foreboding feeling coming. Yesterday, the sector closed with a weak aftermarket after what I call a skimpy session while Q3 slowly ebbs next week” … https://www.regmedinvestors.com/articles/12107
Pre-open indication results: 4 Hits: < CRISP Therapeutics (CRSP +$3.44), Editas Medicine (EDIT +$2.96), Global Blood Therapeutics (GBT +$0.38), Fate Therapeutics (FATE - $0.03) and 2 MISS: < Solid Biosciences (SLDB -$0.04), Biostage (BSTG +$0.06)
The Biostage (BSTG) Chronicles: “The Biostage (BSTG) Chronicles - Maintaining Sell - Is this another Theranos – faking it to not make it?” … https://www.regmedinvestors.com/articles/12087
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
- Net Income: 3 and Net losses: 24
- Applied Genetic Technologies (AGTC) reported today
Key Metric - volume:
- Sector volume was LOW with 3 of the 29-upside having higher than the 3-month average volume with Non-Existent volume of 2 of 5-downside having higher than the 3-month average volume;
The Biostage (BSTG) Chronicles: WHAT happened to the usual “pump/promote”?
Thursday closed up +$0.06 with 839 shares traded after Wednesday closed down -$0.45 with 3,833 shares traded, Tuesday closed up +$0.25 with 654 shares traded and Monday closed down -$0.26 to $3.40 with 563 shares traded.
- Proves my “facts” of the “pump/promote” actions; why hasn’t the SEC questioned who or which entity is buying these shares – there is a definite pattern?
- WERE BSTG’s Q2 8-K and 10-Q filings AUDITED or UNAUDITED for investors?
There are clear winners and losers
Jumping with share pricing momentum:
- Intellia Therapeutics (NTLA) – another again, Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP), Editas Medicine (EDIT), Sage Therapeutics (SAGE) to name 5 of the 29 inclining of the 35 covered
Hammered in today’s market:
- ReNeuron (RENE.L), uniQure NV (QURE), AxoGen (AXGN), Solid Biosciences (SLDB), Fate Therapeutics (FATE) to name 5 of the 5 declining of the 35 covered
Closing flat:
- 1 - Stemline Therapeutics (STML) – acquired
Stats:
The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:
- Thursday, the IBB closed up +1.35% and XBI closed up +1.88%
The CBOE Volatility Index (VVIX: INDEX) tracked:
- Thursday was down -2.24 points or -10.73% at 18.63
September, the third month of Q3/21:
Thursday closed positive with 29 advancers, 5 decliners and 1 acquired
Wednesday closed positive with 18 advancers, 14 decliners, 2 flat and 1 acquired
Tuesday closed positive with 22 advancers, 9 decliners, 2 flats and 1 acquired
Monday (9/20) closed negative with 1 advancer, 33 decliners and 1 acquired
The BOTTOM LINE: Today, the sector swooned bolstered by a rallying market.
Investors were still mulling implications on-going political antics. It’s going to “bite” and hard!
Yesterday, the oversold became the overbought; but who were the buyers – the capricious and profit seeking electronic trading” machines”.
Sentiment is languishing even though the sector rebounded.
My issue is the sector seems to be still under pressure.
The stem, cell and gene therapy sector is still seen as vulnerable to extreme moves in either direction, overbought and oversold categories as risk stimulates the susceptibility!
I’m STILL a “beware or the cautious man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim any new highs if one can!”
WHY do I keep analyzing Biostage (BSTG): When one sees an inextricable wrong and morally repulsive scenario; it takes courage, resolve and patience to stay the course of asking the questions without response!
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
